PMC:7200337 / 84416-85462 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T691","span":{"begin":104,"end":112},"obj":"Body_part"},{"id":"T692","span":{"begin":169,"end":171},"obj":"Body_part"},{"id":"T693","span":{"begin":394,"end":396},"obj":"Body_part"},{"id":"T694","span":{"begin":602,"end":604},"obj":"Body_part"}],"attributes":[{"id":"A691","pred":"fma_id","subj":"T691","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A692","pred":"fma_id","subj":"T692","obj":"http://purl.org/sig/ont/fma/fma284995"},{"id":"A693","pred":"fma_id","subj":"T693","obj":"http://purl.org/sig/ont/fma/fma284995"},{"id":"A694","pred":"fma_id","subj":"T694","obj":"http://purl.org/sig/ont/fma/fma284995"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T485","span":{"begin":95,"end":99},"obj":"Disease"},{"id":"T486","span":{"begin":347,"end":355},"obj":"Disease"},{"id":"T487","span":{"begin":362,"end":370},"obj":"Disease"},{"id":"T488","span":{"begin":373,"end":382},"obj":"Disease"},{"id":"T489","span":{"begin":507,"end":515},"obj":"Disease"},{"id":"T490","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T491","span":{"begin":655,"end":659},"obj":"Disease"},{"id":"T492","span":{"begin":790,"end":794},"obj":"Disease"},{"id":"T493","span":{"begin":957,"end":965},"obj":"Disease"},{"id":"T494","span":{"begin":1021,"end":1029},"obj":"Disease"}],"attributes":[{"id":"A485","pred":"mondo_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A486","pred":"mondo_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A488","pred":"mondo_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A489","pred":"mondo_id","subj":"T489","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A490","pred":"mondo_id","subj":"T490","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A491","pred":"mondo_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A492","pred":"mondo_id","subj":"T492","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A493","pred":"mondo_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A494","pred":"mondo_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T913","span":{"begin":35,"end":43},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T914","span":{"begin":254,"end":255},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T915","span":{"begin":291,"end":296},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T916","span":{"begin":298,"end":299},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T917","span":{"begin":471,"end":472},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T918","span":{"begin":629,"end":630},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T919","span":{"begin":980,"end":992},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T250","span":{"begin":45,"end":60},"obj":"Chemical"},{"id":"T251","span":{"begin":62,"end":65},"obj":"Chemical"},{"id":"T252","span":{"begin":74,"end":82},"obj":"Chemical"},{"id":"T253","span":{"begin":169,"end":171},"obj":"Chemical"},{"id":"T254","span":{"begin":394,"end":396},"obj":"Chemical"},{"id":"T255","span":{"begin":602,"end":604},"obj":"Chemical"},{"id":"T256","span":{"begin":937,"end":952},"obj":"Chemical"}],"attributes":[{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A251","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A252","pred":"chebi_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_73462"},{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_73462"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_73462"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T49","span":{"begin":104,"end":118},"obj":"Phenotype"}],"attributes":[{"id":"A49","pred":"hp_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T195","span":{"begin":263,"end":278},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2791","span":{"begin":394,"end":396},"obj":"Gene"},{"id":"2792","span":{"begin":169,"end":171},"obj":"Gene"},{"id":"2793","span":{"begin":602,"end":604},"obj":"Gene"},{"id":"2794","span":{"begin":323,"end":331},"obj":"Species"},{"id":"2795","span":{"begin":337,"end":345},"obj":"Species"},{"id":"2796","span":{"begin":347,"end":355},"obj":"Species"},{"id":"2797","span":{"begin":543,"end":551},"obj":"Species"},{"id":"2798","span":{"begin":641,"end":649},"obj":"Species"},{"id":"2799","span":{"begin":804,"end":812},"obj":"Species"},{"id":"2800","span":{"begin":95,"end":99},"obj":"Disease"},{"id":"2801","span":{"begin":362,"end":382},"obj":"Disease"},{"id":"2802","span":{"begin":434,"end":443},"obj":"Disease"},{"id":"2803","span":{"begin":507,"end":527},"obj":"Disease"},{"id":"2804","span":{"begin":565,"end":574},"obj":"Disease"},{"id":"2805","span":{"begin":655,"end":659},"obj":"Disease"},{"id":"2806","span":{"begin":957,"end":965},"obj":"Disease"},{"id":"2807","span":{"begin":1021,"end":1029},"obj":"Disease"}],"attributes":[{"id":"A2791","pred":"tao:has_database_id","subj":"2791","obj":"Gene:1431"},{"id":"A2792","pred":"tao:has_database_id","subj":"2792","obj":"Gene:1431"},{"id":"A2793","pred":"tao:has_database_id","subj":"2793","obj":"Gene:1431"},{"id":"A2794","pred":"tao:has_database_id","subj":"2794","obj":"Tax:9606"},{"id":"A2795","pred":"tao:has_database_id","subj":"2795","obj":"Tax:1335626"},{"id":"A2796","pred":"tao:has_database_id","subj":"2796","obj":"Tax:694009"},{"id":"A2797","pred":"tao:has_database_id","subj":"2797","obj":"Tax:9606"},{"id":"A2798","pred":"tao:has_database_id","subj":"2798","obj":"Tax:9606"},{"id":"A2799","pred":"tao:has_database_id","subj":"2799","obj":"Tax:9606"},{"id":"A2800","pred":"tao:has_database_id","subj":"2800","obj":"MESH:D012128"},{"id":"A2801","pred":"tao:has_database_id","subj":"2801","obj":"MESH:C000657245"},{"id":"A2802","pred":"tao:has_database_id","subj":"2802","obj":"MESH:D003643"},{"id":"A2803","pred":"tao:has_database_id","subj":"2803","obj":"MESH:C000657245"},{"id":"A2804","pred":"tao:has_database_id","subj":"2804","obj":"MESH:D003643"},{"id":"A2805","pred":"tao:has_database_id","subj":"2805","obj":"MESH:D012128"},{"id":"A2806","pred":"tao:has_database_id","subj":"2806","obj":"MESH:C000657245"},{"id":"A2807","pred":"tao:has_database_id","subj":"2807","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}

{"project":"LitCovid-sentences","denotations":[{"id":"T482","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T483","span":{"begin":120,"end":297},"obj":"Sentence"},{"id":"T484","span":{"begin":298,"end":470},"obj":"Sentence"},{"id":"T485","span":{"begin":471,"end":688},"obj":"Sentence"},{"id":"T486","span":{"begin":689,"end":836},"obj":"Sentence"},{"id":"T487","span":{"begin":837,"end":1001},"obj":"Sentence"},{"id":"T488","span":{"begin":1002,"end":1046},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a). Yet, new data from COVID-19 are conflicting."}